COVID-19: Outbreak, Advancements and Possibilities
Paper Details
COVID-19: Outbreak, Advancements and Possibilities
Abstract
Coronaviruses are diverse, positive-natured viruses containing RNA, which belong to a family Coronaviridae, that cause various diseases in humans, birds and several other wild animals, causing gastrointestinal, nervous system and respiratory tract infections. COVID-19 pandemic started from Wuhan in December 2019. It advanced to many other countries in a couple of weeks. Coronaviruses are RNA-containing viruses that vary in size from 27 to 32 kb. They are grouped into four genera, namely, alpha, beta, gamma and delta coronavirus targeting different hosts. Previously, six types of coronaviruses were identified to affect humans and produce respiratory tract infections, i.e., HCoV-229E, HCoV-NL63, HCoV-OC43, and HKU1 that affect upper respiratory tract with mild infection while SARS-CoV and MERS-CoV affecting lower respiratory tract with severe infection, were identified leading to morbidity and mortality. The causative agent of COVID-19 is SARS-COV2. The virion is an enveloped particle. It contains a single RNA strand with 30,000 nucleotides. The most common clinical features of COVID-19 are respiratory, gastrointestinal, neurological, cardiovascular and hematological manifestations. Numerous laboratory tests have been developed for the significant diagnosis of COVID-19, such as RT-PCR, Serology, Radiography, and CT- imaging. This review also describes available treatment strategies to counter COVID-19. The previous literature was thoroughly analyzed to design this review. To deal with this pandemic, further investigation about its treatment and genera is mandatory.
Arteaga-Livias K, Pecho-Silva S, Panduro-Correa V, Rodríguez-Morales AJ. 2020. The dilemmas of the classification of SARS-CoV-2 infection without clinical manifestations: Asymptomatic or presymptomatic. Journal of the Formosan Medical Association 119(7), 1237. http://dx.doi.org/10.1016/j.jfma.2020.05.009
Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DA, Alabdullatif ZN, Assad M, Almulhim A, Makhdoom H. 2013. Hospital outbreak of Middle East respiratory syndrome coronavirus. New England Journal of Medicine. 369(5), 407-416. http://dx.doi.org/10.1056/NEJMoa1306742
Bogoch II, Watts A, Thomas-Bachli A, Huber C, Kraemer MU, Khan K. 2020. Pneumonia of unknown aetiology in Wuhan, China: potential for international spread via commercial air travel. Journal of travel medicine 27(2), taaa008. (https://doi.org/10.1093/jtm/taaa008)
Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, Bolling MC, Dijkstra G, Voors AA, Osterhaus AD. 2020. Angiotensin‐converting enzyme 2 (ACE2), SARS‐CoV‐2 and the pathophysiology of coronavirus disease 2019 (COVID‐19). The Journal of pathology. 251(3), 228-248. https://doi.org/10.1002/path.5471
Brodie D, Slutsky AS, Combes A. 2019. Extracorporeal life support for adults with respiratory failure and related indications: a review. jama. 322(6), 557-568. http://dx.doi.org/10.1001/jama.2019.9302
Cascella M, Rajnik M, Aleem A, Dulebohn S, Di Napoli R. 2022. Features, evaluation, and treatment of coronavirus (COVID-19). Stat Pearls.
Cerquaglia C, Diaco M, Nucera G, Regina M, Montalto M, Manna R. 2005. Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update. Current Drug Targets-Inflammation & Allergy 4(1), 117-124.
Chen Y, Liu Q, Guo D. 2020. Emerging coronaviruses: genome structure, replication, and pathogenesis. Journal of medical virology 92(4), 418-423. https://doi.org/10.1002/jmv.25681
Cheng MP, Papenburg J, Desjardins M, Kanjilal S, Quach C, Libman M, Dittrich S, Yansouni CP. 2020a. Diagnostic testing for severe acute respiratory syndrome–related coronavirus 2: a narrative review. Annals of Internal Medicine. 172(11), 726-734. https://doi.org/10.7326/M20-1301
Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, Li J, Yao Y, Ge S, Xu G. 2020b. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney international 97(5), 829-838. https://doi.org/10.1016/j.kint.2020.03.005
Chu C, Cheng V, Hung I, Wong M, Chan K, Chan K, Kao R, Poon L, Wong C, Guan Y. 2004. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59(3), 252-256. http://dx.doi.org/10.1136/thorax.2003.012658
Chung M, Bernheim A, Mei X, Zhang N, Huang M, Zeng X, Cui J, Xu W, Yang Y, Fayad ZA. 2020. CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology 295(1), 202-207. https://doi.org/10.1148/radiol.2020200230
Commission NH, Medicine NAoTC. 2020. Diagnosis and treatment protocol for novel coronavirus pneumonia (Trial Version 7). Chinese medical journal. 133(09), 1087-1095. https://doi.org/10.1097/CM9.0000000000000819
Corey L, Mascola JR, Fauci AS, Collins FS. 2020. A strategic approach to COVID-19 vaccine R&D. Science. 368(6494), 948-950. http://dx.doi.org/10.1126/science.abc5312
Coronavirus F. 2020. Update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine. 2020. In.
Cruz AT, Zeichner SL. 2020. COVID-19 in children: initial characterization of the pediatric disease. Pediatrics. 145(6). https://doi.org/10.1542/peds.2020-0834
Cui J, Li F, Shi ZL. 2019. Origin and evolution of pathogenic coronaviruses. Nature Reviews Microbiology 17(3), 181-192.
Curfman G. 2020. Renin-angiotensin-aldosterone inhibitors and susceptibility to and severity of COVID-19. jama. 324(2), 177-178. http://dx.doi.org/10.1001/jama.2020.11401
Devaux CA, Rolain J-M, Colson P, Raoult D. 2020. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? International journal of antimicrobial agents 55(5), 105938. https://doi.org/10.1016/j.ijantimicag.2020.105938
Dong E, Du H, Gardner L. 2020a. An interactive web-based dashboard to track COVID-19 in real time. The Lancet infectious diseases. 20(5), 533-534. https://doi.org/10.1016/S1473-3099(20)30120-1
Dong L, Hu S, Gao J. 2020b. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug discoveries & therapeutics 14(1), 58-60. https://doi.org/10.5582/ddt.2020.01012
Feng G, Zheng KI, Yan QQ, Rios RS, Targher G, Byrne CD, Van Poucke S, Liu WY, Zheng MH. 2020. COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies. Journal of clinical and translational hepatology. 8(1), 18. http://dx.doi.org/10.14218/JCTH.2020.00018
Gautier JF, Ravussin Y. 2020. A new symptom of COVID‐19: loss of taste and smell. Obesity 28(5), 848-848. http://dx.doi.org/10.1002/oby.22809
Goligher EC, Tomlinson G, Hajage D, Wijeysundera DN, Fan E, Jüni P, Brodie D, Slutsky AS, Combes A. 2018. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome and posterior probability of mortality benefit in a post hoc Bayesian analysis of a randomized clinical trial. jama 320(21), 2251-2259. http://dx.doi.org/10.1001/jama.2018.14276
Graci JD, Cameron CE. 2006. Mechanisms of action of ribavirin against distinct viruses. Reviews in medical virology 16(1), 37-48. https://doi.org/10.1002/rmv.483
Graham BS. 2020. Rapid COVID-19 vaccine development. Science. 368(6494), 945-946. http://dx.doi.org/10.1126/science.abb8923
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX. 2020. Compassionate use of remdesivir for patients with severe Covid-19. New England Journal of Medicine. 382(24), 2327-2336. http://dx.doi.org/10.1056/NEJMoa2007016
Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, Dela Cruz CS, Wang Y, Wu C, Xiao Y. 2020. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clinical infectious diseases 71(15), 778-785. https://doi.org/10.1093/cid/ciaa310
He G, Li Q, Li W, Ruan Y, Xiong X, Song X, Zeng F. 2020. Effect of ulinastatin on interleukins and pulmonary function in bypass patients: a meta-analysis of randomized controlled trials. Herz. 45(4), 335-346. https://doi.org/10.1007/s00059-018-4732-0
Hernández G, Ospina-Tascón GA, Damiani LP, Estenssoro E, Dubin A, Hurtado J, Friedman G, Castro R, Alegría L, Teboul JL. 2019. Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28-day mortality among patients with septic shock: the ANDROMEDA-SHOCK randomized clinical trial. jama 321(7), 654-664. http://dx.doi.org/10.1001/jama.2019.0071
Ho CS, Chee CY, Ho RC. 2020. Mental health strategies to combat the psychological impact of COVID-19 beyond paranoia and panic. Ann Acad Med Singapore. 49(1), 1-3.
Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, Wiselka M, Ustianowski A, Elmahi E, Prudon B. 2020. Effect of hydroxychloroquine in hospitalized patients with COVID-19: preliminary results from a multi-centre, randomized, controlled trial. MedRxiv. https://doi.org/10.1101/2020.07.15.20151852
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 395(10223), 497-506. https://doi.org/10.1016/S0140-6736(20)30183-5
Javed B, Sarwer A, Soto EB, Mashwani ZUR. 2020. Is Pakistan’s response to coronavirus (SARS-CoV-2) adequate to prevent an outbreak? Frontiers in medicine 7, 158. https://doi.org/10.3389/fmed.2020.00158
Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA, Klassen SA, Carter RE, Klompas AM, Wiggins CC, Shepherd JR. 2020. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. The Journal of clinical investigation 130(9). https://doi.org/10.1172/JCI140200.
Kalil AC, Sun J. 2011. Low-dose steroids for septic shock and severe sepsis: the use of Bayesian statistics to resolve clinical trial controversies. Intensive care medicine 37(3), 420-429. (https://doi.org/10.1007/s00134-010-2121-0)
Kampf G, Todt D, Pfaender S, Steinmann E. 2020. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. Journal of hospital infection. 104(3), 246-251. https://doi.org/10.1016/j.jhin.2020.01.022
Lai CC, Liu YH, Wang CY, Wang YH, Hsueh S-C, Yen MY, Ko WC, Hsueh PR. 2020. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. Journal of Microbiology, Immunology and Infection. 53(3), 404-412. https://doi.org/10.1016/j.jmii.2020.02.012
Lai MM, Cavanagh D. 1997. The molecular biology of coronaviruses. Advances in virus research 48, 1-100. https://doi.org/10.1016/S0065-3527(08)60286-9)
Landrigan PJ, Fuller R, Acosta NJ, Adeyi O, Arnold R, Baldé AB, Bertollini R, Bose-O’Reilly S, Boufford JI, Breysse PN. 2018. The Lancet Commission on pollution and health. The Lancet. 391(10119), 462-512. https://doi.org/10.1016/S0140-6736(17)32345-0
Leung YY, Hui LLY, Kraus VB. editors. Seminars in arthritis and rheumatism. 2015.
Li L, Qin L, Xu Z, Yin Y, Wang X, Kong B, Bai J, Lu Y, Fang Z, Song Q. 2020a. Artificial intelligence distinguishes COVID-19 from community acquired pneumonia on chest CT. Radiology. http://dx.doi.org/10.1148/radiol.2020200905
Li X, Geng M, Peng Y, Meng L, Lu S. 2020b. Molecular immune pathogenesis and diagnosis of COVID-19. Journal of pharmaceutical analysis. 10(2), 102-108. https://doi.org/10.1016/j.jpha.2020.03.001
Long B, Brady WJ, Koyfman A, Gottlieb M. 2020. Cardiovascular complications in COVID-19. The American journal of emergency medicine 38(7), 1504-1507. https://doi.org/10.1016/j.ajem.2020.04.048
Marques‐da‐Silva C, Chaves M, Castro N, Coutinho‐Silva R, Guimaraes M. 2011. Colchicine inhibits cationic dye uptake induced by ATP in P2X2 and P2X7 receptor‐expressing cells: implications for its therapeutic action. British journal of pharmacology 163(5), 912-926. https://doi.org/10.1111/j.1476-5381.2011.01254.x
Martínez GJ, Robertson S, Barraclough J, Xia Q, Mallat Z, Bursill C, Celermajer DS, Patel S. 2015. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. Journal of the American Heart Association 4(8), e002128. https://doi.org/10.1161/JAHA.115.002128
McIntosh K, Hirsch MS, Bloom A. 2020. Coronavirus disease 2019 (COVID-19). UpToDate Hirsch MS Bloom 5(1).
Moon S, Røttingen JA, Frenk J. 2017. Global public goods for health: weaknesses and opportunities in the global health system. Health Economics, Policy and Law 12(2), 195-205.
Moreno G, Rodríguez A, Reyes LF, Gomez J, Sole-Violan J, Díaz E, Bodí M, Trefler S, Guardiola J, Yébenes JC. 2018. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study. Intensive care medicine 44(9), 1470-1482. https://doi.org/10.1007/s00134-018-5332-4
Nay O. 2020. The global health we need, the WHO we deserve. In: Graduate Institute of International and Development Studies, Global Health.
Ohannessian R, Duong TA, Odone A. 2020. Global telemedicine implementation and integration within health systems to fight the COVID-19 pandemic: a call to action. JMIR public health and surveillance 6(2), e18810.
Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, Scarlata S, Agrò FE. 2020. COVID‐19 diagnosis and management: a comprehensive review. Journal of internal medicine. 288(2), 192-206. https://doi.org/10.1111/joim.13091
Peiris JS, Guan Y, Yuen KY. 2004. Severe acute respiratory syndrome. Nature medicine. 10(12), S88-S97. https://doi.org/10.1038/nm1143
Rajkumar RP. 2020. COVID-19 and mental health: A review of the existing literature. Asian journal of psychiatry 52, 102066. https://doi.org/10.1016/j.ajp.2020.102066
Robertson S, Martínez GJ, Payet CA, Barraclough JY, Celermajer DS, Bursill C, Patel S. 2016. Colchicine therapy in acute coronary syndrome patients acts on caspase-1 to suppress NLRP3 inflammasome monocyte activation. Clinical science. 130(14), 1237-1246. https://doi.org/10.1042/CS20160090
Rodriguez-Morales AJ, Bonilla-Aldana DK, Balbin-Ramon GJ, Rabaan AA, Sah R, Paniz-Mondolfi A, Pagliano P, Esposito S. 2020. History is repeating itself: Probable zoonotic spillover as the cause of the 2019 novel Coronavirus Epidemic. Infez Med. 28(1), 3-5.
Rothan HA, Byrareddy SN. 2020. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of autoimmunity 109, 102433. https://doi.org/10.1016/j.jaut.2020.102433
Ruan Q, Yang K, Wang W, Jiang L, Song J. 2020. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive care medicine 46(5), 846-848. https://doi.org/10.1007/s00134-020-05991-x
Salman M, Mustafa ZU, Asif N, Zaidi HA, Hussain K, Shehzadi N, Khan TM, Saleem Z. 2020. Knowledge, attitude and preventive practices related to COVID-19: a cross-sectional study in two Pakistani university populations. Drugs & Therapy Perspectives 36(7), 319-325. https://doi.org/10.1007/s40267-020-00737-7
Saqlain M, Munir MM, Ahmed A, Tahir AH, Kamran S. 2020. Is Pakistan prepared to tackle the coronavirus epidemic? Drugs & Therapy Perspectives. 1. https://doi.org/10.1007/s40267-020-00721-1
Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. 2006. New insights into the antiviral effects of chloroquine. The Lancet infectious diseases. 6(2), 67-69. https://doi.org/10.1016/S1473-3099(06)70361-9
Shaila M. 2003. Severe acute respiratory syndrome (SARS): an old virus jumping into a new host or a new creation? Journal of biosciences 28(4), 359-360.
Slutsky AS, Ranieri VM. 2014. Ventilator-induced lung injury. The New England journal of medicine. 370(10), 980-980. https://doi.org/10.1056/nejmc1400293
Song Y, Liu P, Shi X, Chu Y, Zhang J, Xia J, Gao X, Qu T, Wang M. 2020. SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19. Gut. 69(6), 1143-1144. http://dx.doi.org/10.1136/gutjnl-2020-320891
Stewart K, Connelly D, Robinson J. 2020. Everything you should know about the coronavirus outbreak. The Pharmaceutical Journal. 30.
Stockman LJ, Bellamy R, Garner P. 2006. SARS: systematic review of treatment effects. PLoS medicine 3(9), e343. https://doi.org/10.1371/journal.pmed.0030343
Su B, Wang Y, Zhou R, Jiang T, Zhang H, Li Z, Liu A, Shao Y, Hua W, Zhang T. 2019. Efficacy and tolerability of lopinavir/ritonavir-and efavirenz-based initial antiretroviral therapy in HIV-1-infected patients in a tertiary care hospital in Beijing, China. Frontiers in pharmacology 10, 1472. https://doi.org/10.3389/fphar.2019.01472
Su S, Wong G, Shi W, Liu J, Lai AC, Zhou J, Liu W, Bi Y, Gao GF. 2016. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends in microbiology 24(6), 490-502. https://doi.org/10.1016/j.tim.2016.03.003
Tian Y, Rong L, Nian W, He Y. 2020. Gastrointestinal features in COVID‐19 and the possibility of faecal transmission. Alimentary pharmacology & therapeutics 51(9), 843-851. https://doi.org/10.1111/apt.15731
Toldo S, Abbate A. 2018. The NLRP3 inflammasome in acute myocardial infarction. Nature Reviews Cardiology 15(4), 203-214. (https://doi.org/10.1038/nrcardio.2017.161
Van De Veerdonk F, Netea MG, Van Deuren M, Van Der Meer JW, De Mast Q, Bruggemann RJ, Van Der Hoeven H. 2020. Kinins and cytokines in COVID-19: a comprehensive pathophysiological approach. https://doi.org/10.20944/preprints202004.0023.v1
Velavan TP, Meyer CG. 2020. The COVID‐19 epidemic. Tropical medicine & international health. 25(3), 278. https://doi.org/10.1111/tmi.13383
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y. 2020a. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. jama 323(11), 1061-1069. https://doi.org/10.1001/jama.2020.1585
Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, Jiang B. 2020b. Comorbidities and multi-organ injuries in the treatment of COVID-19. The Lancet. 395(10228), e52. https://doi.org/10.1016/S0140-6736(20)30558-4
Wang W, Tang J, Wei F. 2020c. Updated understanding of the outbreak of 2019 novel coronavirus (2019‐nCoV) in Wuhan, China. Journal of medical virology 92(4), 441-447. https://doi.org/10.1002/jmv.25689
Waris A, Atta U, Ali M, Asmat A, Baset A. 2020. COVID-19 outbreak: current scenario of Pakistan. New Microbes and New Infections 35, 100681. https://doi.org/10.1016/j.nmni.2020.100681
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, Graham BS, McLellan JS. 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367(6483), 1260-1263. https://doi.org/10.1126/science.abb2507
Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y. 2020a. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA internal medicine 180(7), 934-943. https://doi.org/10.1001/jamainternmed.2020.0994
Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, Liu C, Yang C. 2020b. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain, behavior, and immunity 87, 18-22. https://doi.org/10.1016/j.bbi.2020.03.031
Wu Z, McGoogan JM. 2020. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. jama 323(13), 1239-1242. https://doi.org/10.1001/jama.2020.2648
Xu X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X. 2020a. Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings of the National Academy of Sciences. 117(20), 10970-10975. https://doi.org/10.1073/pnas.2005615117
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L. 2020b. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet respiratory medicine. 8(4), 420-422. https://doi.org/10.1016/S2213-2600(20)30076-X
Yang W, Yan F. 2020. Patients with RT-PCR-confirmed COVID-19 and normal chest CT. Radiology 295(2), E3-E3. https://doi.org/10.1148/radiol.2020200702
Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T. 2020. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet respiratory medicine 8(5), 475-481. https://doi.org/10.1016/S2213-2600(20)30079-5
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C. 2020. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical infectious diseases 71(15), 732-739. https://doi.org/10.1093/cid/ciaa237
Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, Ng O-T, Marimuthu K, Ang LW, Mak TM. 2020. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. jama. 323(15), 1488-1494. https://doi.org/10.1001/jama.2020.3204
Yuki K, Fujiogi M, Koutsogiannaki S. 2020. COVID-19 pathophysiology: A review. Clinical immunology 215, 108427. https://doi.org/10.1016/j.clim.2020.108427
Zachariah P, Johnson CL, Halabi KC, Ahn D, Sen AI, Fischer A, Banker SL, Giordano M, Manice CS, Diamond R. 2020. Epidemiology, clinical features, and disease severity in patients with coronavirus disease 2019 (COVID-19) in a children’s hospital in New York City, New York. JAMA pediatrics 174(10), e202430-e202430. https://doi.org/10.1001/jamapediatrics.2020.2430
Zha L, Li S, Pan L, Tefsen B, Li Y, French N, Chen L, Yang G, Villanueva EV. 2020. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID‐19). Medical Journal of Australia 212(9), 416-420. https://doi.org/10.5694/mja2.50577
Zhao M. 2020. Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies. International journal of antimicrobial agents 55(6) 105982. https://doi.org/10.1016/j.ijantimicag.2020.105982
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X. 2020a. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 395(10229), 1054-1062.
Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L. 2020b. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 579(7798), 270-273. https://doi.org/10.1038/s41586-020-2012-7
Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. 2020. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA neurology 77(8), 1018-1027. https://doi.org/10.1001/jamaneurol.2020.2065
Zumla A, Hui DS, Perlman S. 2015. Middle East respiratory syndrome. The Lancet. 386(9997), 995-1007. https://doi.org/10.1016/S0140-6736(15)60454-8
Fahad Asim, Muhammad Sameer Ashaq, Humayun Riaz, Syed Atif Raza, Abdul Raheem Malik, Umer Farooq, Rana Khalid Mehmood, Syed Ali Faran, Muzammil Raza (2022), COVID-19: Outbreak, Advancements and Possibilities; IJB, V20, N2, February, P210-228
https://innspub.net/covid-19-outbreak-advancements-and-possibilities/
Copyright © 2022
By Authors and International
Network for Natural Sciences
(INNSPUB) https://innspub.net
This article is published under the terms of the
Creative Commons Attribution License 4.0